Ventus launches to drug inflammasomes and more

Ventus Therapeutics launches to drug inflammasomes, cGAS, and ...

Drug Discovery. Ventus Therapeutics launches to drug inflammasomes, cGAS, and more. The Versant-founded start-up raised $60 million to develop ...

Ventus launches to drug inflammasomes and more - ACS Publications

The Versant-founded start-up raised $60 million to develop small molecules that target innate immune system proteins ... Ventus Therapeutics has launched with $60 ...

Ventus Therapeutics Launches with $60 Million Series A

Founded by Versant Ventures to develop medicines that target the innate immune system · Drugging the inflammasome and nucleic acid-sensing ...

Ventus Therapeutics Announces Successful Completion of Phase 1 ...

“Available treatments for lupus today include injectable medicines for the type I interferon or BAFF pathways that address only limited aspects ...

Ventus Therapeutics Announces Publication in Journal of ...

... Medicine Describing Advances in Structure-based Drug Discovery for Inflammasome Targets ... “Having a more precise view of inflammasome proteins may ...

Novo enters NLRP3 arena, paying Ventus $70M for NASH hopeful

... drug discovery at Novo Nordisk, in a Sept. 29 release. “Ventus has ... See more articles. Home. Connect. The Team · Advertise. Join Us.

Ventus Scoops Up $100 Million to Take NLRP3 Inhibitor to the Clinic

... drug this particular inflammasome. NodThera secured $55 million in ... more. The diverse range of disease makes the biotech a prime ...

Ventus sells its lead drug candidate to Novo Nordisk | BioPharma Dive

The experimental drug, dubbed VENT-01, is a small molecule that targets inflammasomes, which are protein complexes in immune system cells that ...

Ventus Therapeutics Enters Exclusive Development and License ...

... Drug Discovery at Novo Nordisk. “Ventus has ... For more information about Ventus' NLRP3 program and pipeline, visit www.VentusTx.com.

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial ...

... drug levels in the CSF for 24 hours, and robust ... NLRP3 is the best understood member of a family of proteins known as inflammasomes.

Ventus raises $100M to pursue NLRP3, crack undruggable targets

The second drug in the pipeline targets NLRP3, an inflammasome protein complex that has attracted a lot of attention. Multiple large and small ...

Novo Nordisk joins Novartis, Roche in NLRP3 arena, betting $70M ...

As a drug target, the NLRP3 inflammasome has drawn serious interest ... There are two main parts to the partnership: Ventus will receive R&D ...

Ventus Therapeutics tacks on $100M to take on 'undruggable ...

... of drugs—much more than a young company can handle on its own. But Ventus won't be adding compounds to its pipeline, at least in the near term.

Ventus Therapeutics Announces First Participant Dosed in Clinical ...

... more. Get Started. Ventus Therapeutics Announces ... NLRP3 is the best understood member of a family of proteins known as inflammasomes.

The Biotech Field That's Getting Big Pharma's Attention at the ...

... Ventus's brain penetrant inflammasome (NLRP3) inhibitor – Ventus is a privately held company that retains full rights. Cerevance – August 9 ...

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial ...

... drug levels in the CSF for 24 hours, and robust ... NLRP3 is the best understood member of a family of proteins known as inflammasomes.

Ventus Therapeutics, Inc. Announces First Participant Dosed in ...

NLRP3 is the best understood member of a family of proteins known as inflammasomes. ... Drug Price Negotiation Program. 5h ago MT. Sector ...

NLRP3 inhibitor for neuroinflammation enters trials

The Phase I clinical trial of VENT-02, an oral, brain-penetrant NLRP3 inhibitor from Ventus Therapeutics, has launched with the dosing of ...

Ventus Therapeutics Announces Phase 1 Results for Brain ...

Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and ...

Ventus Therapeutics Launches with $60 Million Series A

... inflammasomes and nucleic acid sensing targets. This in turn enables ... drug discovery team equipped with know-how and capabilities in ...